HemispherxBioPharma, Inc (NYSEMKT:HEB) Inches Up; Gets ‘Buy’

Posted by Lacee Page January 24, 2014 0 Comment 763 views


HemispherxBioPharma, Inc (NYSEMKT:HEB) continued to rally for the second straight session on Thursday, as it surged by almost 20%, reaching a new 52 week high of  $0.55 per share. For the past couple of days, the stock prices have been reflecting the company’s announcement of Dr. William M. Mitchell’s presentation of research paper, covering the subject matter of Pulmonary Tissue Damage in connection with infection caused by  Avian Influenza Virus (H5N1) and its protection by Low Dose Natural Human IFN.

A Note About The Presentation

The presentation highlighted the growing concern of the global threat of an influenza epidemic caused by the avian ‘H5N1’ and ‘H7N9’ influenza virus. The  threat being of devastating nature, to the humans has pushed to the object of devising methods to encounter these virus. The collaborative team has successfully reported to have tested the success of a low dose oral preparation of alpha Alferon N Injection(R), which could significantly mitigate the pulmonary damage caused by the primary influenza virus.

Chardan Capital’s Coverage

This is followed by a coverage initiation from Chardan Capital, who have placed a ‘buy’ rating for the company and has put a price target of $3 per share, in their research report.

Hemispherx Biopharma, Inc. is a progressive specialty pharmaceutical firm, which is engaged in the manufacturing as well as the clinical development of innovative drug therapies, to treat serious incapacitating disorders. The company focus on treating these disorders through enhancing natural immune system, more particularly for the viral and immune related diseases.  Some of the Hemispherx’s lead products are Alferon N Injection®, Alferon® LDO and the experimental therapeutics Ampligen®. Ampligen® is an experimental  product with RNA nucleic acid, which is developed for hindering system diseases and disorders related to the immune system  which includes Chronic Fatigue Syndrome. Since, Ampligen® and Alferon® LDO, both are experimental; thus they are not labelled safe and effective.  It is only available through clinical trials



About Lacee Page

Lacee Page is our White House and political campaign reporter. Lacee also covers justice and national law enforcement issues and congressional reporter focusing on the outputs of the legislative process: government spending, agency regulation and congressional oversight. Lacee received a national Edward R. Murrow for spot news award and the regional Associated Press award for best newscast. Lacee attended Riverview High School near Coshocton, and graduated from Ashland College in Ashland, Ohio with a Bachelor of Arts degree in Communications.

View all post by Lacee Page Visit author's website

Write Your Comment